双激酶抑制剂ITRI-E-(S)4046在眼压升高动物模型中的降眼压作用
本研究开发了肌球蛋白轻链激酶4(MYLK4)与Rho相关蛋白激酶(ROCK)双重协同抑制剂ITRI-E-(S)4046,并在正常眼压兔、正常眼压非人灵长类及高眼压兔中评估其降眼压效果与耐受性。0.1%滴眼液在正常眼压兔和非人灵长类的平均降眼压幅度分别为29.8%和28.5%,在高渗盐水诱导和磁珠诱导高眼压兔中分别为46.9%和22.0%,仅见暂时性轻微充血。
要点
- 0.1% ITRI-E-(S)4046对ROCK1/2、MYLK4、MAP3K19具高选择性抑制作用。
- 正常眼压兔与非人灵长类平均降眼压分别为29.8%与28.5%。
- 高渗盐水及磁珠诱导高眼压兔平均降眼压分别为46.9%与22.0%。
核心结论
- ITRI-E-(S)4046是新型高特异性ROCK1/2与MYLK4抑制剂,可在正常眼压和高眼压动物模型中降低眼压。
- 作者认为其有潜力成为有效且耐受性良好的青光眼治疗药物。
研究设计与样本
- 临床前研究:采用Kinase-Glo发光激酶试验评估体外激酶抑制活性,并用DiscoverRx的KINOMEscan进行激酶选择性分析。
- 在正常眼压兔、正常眼压非人灵长类和高眼压兔中评估0.1% ITRI-E-(S)4046滴眼液的降眼压效果与耐受性。
- 开展体内研究评估眼组织药物浓度,并按OECD405指南评价兔眼不良作用。
主要发现
- ITRI-E-(S)4046对ROCK1/2、MYLK4和MAP3K19显示高选择性激酶抑制活性,对蛋白激酶A、G、C家族具高特异性。
- 正常眼压兔中0.1% ITRI-E-(S)4046滴眼液平均降眼压29.8%,正常眼压非人灵长类为28.5%。
- 高渗盐水诱导高眼压兔中0.1% ITRI-E-(S)4046平均降眼压46.9%,磁珠诱导高眼压兔为22.0%。
- ITRI-E-(S)4046耐受性良好,仅出现暂时性轻微充血体征。
关键数值与推荐
- 0.1% ITRI-E-(S)4046滴眼液在正常眼压兔的平均降眼压为29.8%,在正常眼压非人灵长类为28.5%。
- 0.1% ITRI-E-(S)4046滴眼液在高渗盐水诱导高眼压兔的平均降眼压为46.9%,在磁珠诱导高眼压兔为22.0%。
临床怎么用
- 目前仅为动物模型临床前证据,尚不能直接推导人眼用药方案与剂量。
- 提示ROCK1/2与MYLK4双重抑制可作为青光眼降眼压药物开发的候选方向。
局限性
- 研究为动物模型临床前研究,未报告人体试验数据。
- 原文未涉及长期用药安全性、全身暴露及与其他降眼压药物的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to develop a preclinical compound, ITRI-E-(S)4046, a dual synergistic inhibitor of myosin light chain kinase 4 (MYLK4) and Rho-related protein kinase (ROCK), for reducing intraocular pressure (IOP). METHODS: ITRI-E-(S)4046 is an amino-pyrazole derivative with physical and chemical properties suitable for ophthalmic formulation. In vitro kinase inhibition was evaluated using the Kinase-Glo Luminescent Kinase Assays. A comprehensive kinase selectivity analysis of ITRI-E-(S)4046 was performed using the KINOMEscan assay from DiscoverRx. The IOP reduction and tolerability of ITRI-E-(S)4046 were assessed in ocular normotensive rabbits, ocular normotensive non-human primates, and ocular hypertensive rabbits. In vivo studies were conducted to assess drug concentrations in ocular tissue. The adverse ocular effects of rabbit eyes were evaluated following the OECD405 guidelines. RESULTS: ITRI-E-(S)4046 showed highly selective kinase inhibitory activity against ROCK1/2, MYLK4, and mitogen-activated protein kinase kinase kinase 19 (MAP3K19), with high specificity against protein kinase A, G, and C families. In ocular normotensive rabbits and non-human primates, the mean IOP reductions of 0.1% ITRI-E-(S)4046 eye drops were 29.8% and 28.5%, respectively. In hypertonic saline-induced and magnetic beads-induced ocular hypertensive rabbits, the mean IOP reductions of ITRI-E-(S)4046 0.1% eye drops were 46.9% and 22.0%, respectively. ITRI-E-(S)4046 was well tolerated with only temporary and minor signs of hyperemia. CONCLUSIONS: ITRI-E-(S)4046 is a novel type of highly specific ROCK1/2 and MYLK4 inhibitor that can reduce IOP in normotensive and hypertensive animal models. It has the potential to become an effective and well-tolerated treatment for glaucoma.
引用
- Chen YH, Lin WY, Huang YC, et al. The Intraocular Pressure Lowering Effect of a Dual Kinase Inhibitor (ITRI-E-(S)4046) in Ocular Hypertensive Animal Models. Invest Ophthalmol Vis Sci. 2021. PMID: 34661609. doi:10.1167/iovs.62.13.12
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。